Provided by Tiger Fintech (Singapore) Pte. Ltd.

CALIDI BIOTHERAPEUTICS INC

0.4973
+0.01723.58%
Post-market: 0.4649-0.0324-6.52%17:57 EDT
Volume:308.08K
Turnover:147.87K
Market Cap:14.16M
PE:-0.17
High:0.5100
Open:0.5100
Low:0.4550
Close:0.4801
Loading ...

Company Profile

Company Name:
CALIDI BIOTHERAPEUTICS INC
Exchange:
AMEX
Establishment Date:
- -
Employees:
28
Office Location:
4475 Executive Drive,Suite 200,San Diego,California,United States
Zip Code:
92121
Fax:
858 794 9605
Introduction:
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Directors

Name
Position
William J. Weber
Chief Executive Officer, President and Chairman
Jeanne Tisinger
Independent Director
Michael C. Ruettgers
Lead Independent Director
William J. Fallon
Independent Director
Thomas A. Vecchiolla
Director

Shareholders

Name
Position
William J. Weber
Chief Executive Officer, President and Chairman
Michael J. Alber
Chief Financial Officer and Secretary